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Poster Session II S277have significant influence. Recipient with TNFB + 252 G allele-
positive was a less significant factor (RR5 1.823, P5 0.063). (3)
Relapse was observed more frequently among patients who had
not previously developed aGVHD (P5 0.03). Except TNFRII
196 T/T genotype in recipients side was related to lower relapse
rate(P5 0.05), no significant association was found between cyto-
kine genes polymorphisms with cGVHD, relapse and overall
survival.
Conclusions: These results, which is the first report of TNFA,
TNFB and TNFRII polymorphic features of Chinese population
with the outcomes of HSCT, suggest an interaction of TNFA-
857, TNFB + 252 genotypes on risk of aGVHD.320
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Although immune cells in cord blood (CB) are immature, several
lines of evidence suggested that they are potentially active from
very early timing post-transplant, such as severe immune reaction
observed at around day 9 (Kishi, Transplantation 2005, Barker,
BMT Tandem meetings 2009), or the impact of HLA disparity
in GVH direction on engraftment failure (Matsuno, Blood 2009).
We conducted a retrospective study to investigate the kinetics of
donor-recipient chimerism and lymphocyte recovery (LR) during
early period after CBT. Data were collected from 109 patients
who underwent first CBT using fludarabine (Flu)-containing regi-
men since June 2007 to Feb. 2009 at Toranomon Hospital. Pa-
tients who had non-malignant diseases, died within 30 days, or
had disease progression before engraftment or within 30 days
post-transplant were excluded, and 47 were subjected to the analy-
sis. 21 out of 26 recipients of unrelated bone marrow (UBM) trans-
planted during the same period were selected as above and were
used as a control. Patients received Flu along with melphalan, bu-
sulfan, and total body irradiation in various combinations. Tacroli-
mus (Tac)+mycophenolate mofetil (n5 42) or Tac alone (n5 5)
were used for CB recipients and Tac+methotrexate was for all
UBM recipients as GVHD prophylaxis. 1 or 2-antigen mismatched
CB units were used at a median 2.56 (1.96-4.31) 107/kg of TNC
and 0.87 (0.4-6.32) 105/kg of CD34+ cells. 45 out of 47 CB recip-
ients achieved neutrophil recovery $500/ml at a median of 22 (13-
43) days, whereas all UBM recipients did at a median of 20 (16-41)
days (P5 0.17). In CB recipients, 30 patients were assessed donor-
recipient chimeric status in 16 days post-transplant, and, remark-
ably, 28 (93%) achieved complete (.90%) donor-type, while in
UBM recipients, 7 were assessed and only 2 (29%) did
(P\.0001). LR was assessed by defining the first day of 3 consecu-
tive blood test showed lymphocyte (Ly) $100/ml as the date of LR.
44 (94%) CB recipients achieved LR at a median of 15 (10-37)
days, while all UBM recipients did at a median of 20 (13-29)
days (P5 0.17). The cumulative incidences of LR achievement
up to day 19 were 646 0.5 in CB and 386 1.2 in UBM recipients
(P5.016). Flow cytometric analysis of Ly at around day 14 (13-17)
post-CBT, assessed in 30 patients, showed CD8+ T cell pedomi-
nance (506 5% of Ly). In conclusion, the results indicate
extremely powerful proliferative potential of CB Ly after transplan-
tation which may surpass that of UBM Ly.321
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a) Background: Allogeneic hematopoietic cell transplantation
(HSCT) is associated with a wide range of complications and late ef-
fects, including secondary solid tumors, of which oral carcinoma is
one of the most common. The purpose of this study was to describe
the clinical characteristics of a large series of patients treated with
HSCT that subsequently developed oral premalignant or malignant
lesions.
b) Methods: The records of patients who received HSCT and
developed oral pre/malignant lesions at 3 centers were reviewed. De-
scriptive statistics included HSCT course including chronic graft-
versus-host disease (cGVHD) and details of oral neoplasm including
presentation, diagnosis and management; survival calculations were
also performed.
c) Results: Twenty-four patients were identified that developed
premalignant (n5 8) or malignant (n5 16) oral mucosal disease
at a median time of 3 and 9 years, respectively. Of the 22 that
had developed cGVHD, 95% (21/22) presented with oral features.
Of those that developed carcinoma, 25% had multifocal involve-
ment. The tongue was the most common site (n5 7; 44%), fol-
lowed by lower lip and buccal mucosa (n5 2; 12% for both
sites). Dysplasia preceded diagnosis of carcinoma in 13% of cases.
Localized recurrence occurred in 29% of cases with 5-year freedom
from recurrence of 46% 6 16. Five-year overall survival was 75%
6 22 for patients with premalignant changes and 67% 6 16 for pa-
tients with carcinoma.
d) Conclusions: Patients undergoing HSCT are at risk of develop-
ing new solid cancers, specifically in the mouth. As the majority of
patients in this series were previously diagnosed with oral cGVHD,
and many cases were multifocal/recurrent, this supports the theory
of field cancerization and suggests that these cancers may be more
aggressive than in non-HSCT patients. In addition, this highlights
the importance of comprehensive oral examination and vigilant fol-
low-up. Further studies examining the biological and molecular
processes of tumor development in this high-risk population are
needed.322
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Based on sequence variation in theUL55 gene that encodes glyco-
protein B (gB), human cytomegalovirus (HCMV) can be classified
into four gB genotypes. Previous studies have suggested there could
be an association betweenCMVgB genotype and clinical outcome in
patients who underwent an allogeneic hematopoietic stem cell trans-
plant (HSCT).
Objectives: The goal of this study was to determine the distri-
bution of gB genotypes in allogeneic HSCT patients with CMV
infection and the effect of gB type on clinical outcome includ-
ing CMV disease. Study design: DNA was extracted directly
from the blood of 41 allogeneic HSCT recipients. Antigen
pp65-HCMV and HCMV-DNA was detected by AGM and
N-PCR, respectively. The gB genotype of CMV was determined
using the polymerase chain reaction to amplify a region of
UL55, followed by restriction analysis based on HinfI and
RsaI digestion.
Results:At a median time of 32 days after the transplant, 32/41
patients (78%) presented active HCMV infection detected by
AGM and/or N-PCR. So far, the distribution of HCMV gB ge-
notypes in 21/32 patients with HCMV active infection was as
follow: gB1, 9/21 (42,9%); gB2, 6/21 (28.6%); gB3, 2/21
(9,5%); gB4, 2/21 (9,5%) and two patients (9,5%) had mixed
